US Patent 11,129,812: Claim Scope, Presbyopia Formulation Coverage, and Patent Landscape

US Patent 11,129,812 is directed to treating presbyopia with a defined ophthalmic composition containing approximately 0.4% pilocarpine hydrochloride, 0.1% sodium hyaluronate, and 0.8% hydroxypropyl methylcellulose. Its principal protection is a method-of-treatment claim tied to both the formulation and the mechanism of action: correction of presbyopia through a change in pupil size.

The patent is commercially significant because the claim reaches a low-dose pilocarpine formulation designed for sustained functional effect, including claims directed to duration, night vision, visual field, delivery form, and specific patient populations. The claim structure also creates potential design-around paths involving concentration, excipient selection, formulation architecture, and treatment method.

What does US Patent 11,129,812 protect?

The patent protects administering a therapeutically effective ophthalmic composition to correct presbyopia when the composition contains all of the following:

Component	Claimed concentration
Pilocarpine hydrochloride	About 0.4% w/w or w/v
Sodium hyaluronate	About 0.1% w/w or w/v
Hydroxypropyl methylcellulose	About 0.8% w/w or w/v
Stabilizers and other excipients	Required by the claim
Sodium chloride, pH agent and water	Included in the claimed carrier system

The independent claim is a method claim rather than a composition claim. An accused product therefore must be used in a manner that satisfies the treatment limitations. Mere manufacture or sale of a formulation may not, by itself, establish infringement of claim 1 unless the relevant jurisdiction recognizes contributory or induced infringement based on the product's intended use and associated conduct.

The core claim has five material limitations:

A subject has presbyopia.
A therapeutically effective amount is administered.
The formulation contains the specified active ingredient and three specified excipients.
The composition includes the stated carrier and stabilizer system.
Presbyopia correction occurs through a change in pupil size.

The concentration language is central. "About 0.4%" permits some numerical variation, but the permissible range depends on intrinsic claim construction, specification support, prosecution history, and the doctrine of equivalents. The phrase should not be treated as an unlimited range around 0.4%.

How broad is claim 1 of US Patent 11,129,812?

Claim 1 is narrower than a general pilocarpine method claim but broader than a claim limited to a single marketed eye-drop product.

It is narrow because it requires the combination of:

Pilocarpine hydrochloride at approximately 0.4%;
Sodium hyaluronate at approximately 0.1%;
Hydroxypropyl methylcellulose at approximately 0.8%; and
The stated ophthalmic carrier and stabilizer framework.

It is broader because it does not expressly require:

A particular brand;
A preservative-free container;
A particular dosing frequency;
A specified bottle or delivery device;
A specific pH value;
A particular particle-size profile;
A particular manufacturing process;
A particular clinical endpoint beyond presbyopia correction through pupil-size change; or
A particular route limited to conventional eye drops.

The claim expressly permits topical administration and surgical intervention through claim 4. Claim 1 itself does not require eye-drop administration. Claims 7 and 8 narrow the protected subject matter to listed dosage forms and then to an eye-drop formulation.

Literal infringement considerations

A product is more exposed when its label, technical documentation, or clinical use identifies:

Pilocarpine hydrochloride at approximately 0.4%;
Sodium hyaluronate and hydroxypropyl methylcellulose at approximately the claimed concentrations;
Use for presbyopia;
Pupil miosis or pupil-size reduction as the mechanism;
Duration claims of up to 8, 12 or 24 hours; and
The patient groups listed in claim 5.

A formulation that omits either sodium hyaluronate or hydroxypropyl methylcellulose should have a stronger literal non-infringement position against claim 1, although the doctrine of equivalents could remain relevant. A formulation using pilocarpine free base rather than pilocarpine hydrochloride presents a separate chemical and claim-construction issue.

What do dependent claims 2 through 12 add?

The dependent claims create several narrower enforcement positions.

Claim	Added limitation	Commercial relevance
2	Sodium hydrogen sulphite and/or EDTA stabilizers	Covers defined stabilization systems
3	Effect for up to 24 hours and/or no adverse effect on night vision	Links formulation to duration and tolerability
4	Topical administration or surgical intervention	Expands administration routes
5	Twelve listed patient categories	Extends use coverage to defined clinical populations
6	Slow-release composition	Covers sustained-delivery architecture
7	Suspension, gel, ointment, injectable solution, spray or eye drop	Covers multiple dosage forms
8	Eye-drop formulation	Most commercially relevant dosage-form claim
9	Topical delivery to the eye or surrounding tissue	Covers periocular topical administration
10	No adverse reduction in visual field	Adds a functional safety limitation
11	Effect for up to 12 hours	Intermediate duration claim
12	Effect for up to 8 hours	Narrower duration claim likely directed to practical daily use

Claim 2: stabilizer coverage

Claim 2 specifies sodium hydrogen sulphite and/or ethylenediaminetetraacetic acids, commonly understood in pharmaceutical formulation practice as EDTA-type chelating agents. The claim may cover either stabilizer individually or mixtures, depending on the construction of the phrase "and/or."

A competing product using a different antioxidant or chelator may avoid literal infringement of claim 2 while remaining exposed under claim 1 if all other limitations are met.

Claims 3, 11 and 12: duration

The duration claims are unusual because "effective for up to 24 hours" can be read as a broad upper-bound statement rather than a minimum duration requirement. Claim construction will determine whether the claim requires efficacy throughout a period, permits efficacy at any point within that period, or merely describes the product's potential duration.

Claim 12, directed to effectiveness for up to eight hours, is commercially important because an eye drop that provides several hours of functional near-vision correction may fall within the practical target of the claim even if it does not provide all-day activity.

The claims do not specify:

The clinical test used to measure effectiveness;
The visual-acuity threshold;
The required pupil diameter;
The number of doses;
The dosing interval; or
Whether efficacy must be demonstrated under photopic, mesopic or scotopic conditions.

Those omissions may create both enforcement flexibility and validity risk under written-description, enablement, definiteness or claim-construction theories.

What formulations are protected by US Patent 11,129,812?

The strongest formulation coverage concerns an eye drop containing the following approximate composition:

0.4% pilocarpine hydrochloride;
0.1% sodium hyaluronate;
0.8% hydroxypropyl methylcellulose;
Sodium chloride;
A pH-adjusting agent;
Water; and
One or more stabilizers, particularly sodium hydrogen sulphite or EDTA.

The claims also reach suspensions, gels, ointments, injectable solutions and sprays through claim 7. That breadth is limited by claim dependency. A product in one of those forms must still satisfy the composition and method limitations inherited from claim 1.

The slow-release claim may cover viscosity-enhanced, mucoadhesive, gel-forming or otherwise sustained-delivery formulations. Sodium hyaluronate and hydroxypropyl methylcellulose can contribute to ocular residence time and rheological properties, but the patent claim does not require a specific viscosity, residence-time measurement or release profile.

Likely formulation design-arounds

Potential design-around strategies include:

Changing pilocarpine concentration materially below or above 0.4%.
Replacing sodium hyaluronate with another viscoelastic polymer.
Replacing hydroxypropyl methylcellulose with carbomer, povidone, polyethylene glycol or another viscosity modifier.
Removing one of the two specified polymers.
Using pilocarpine nitrate or another salt, subject to the scope of any related patent claims.
Changing the stabilizer system.
Using a formulation that does not rely on pupil-size change as the claimed corrective mechanism.
Using a different active ingredient, such as an alternative miotic or pharmacologic presbyopia therapy.
Delivering the active ingredient through a device or implant with materially different formulation characteristics.

These strategies do not guarantee freedom to operate. Related continuation, divisional or foreign-family patents may contain broader composition, process, device or use claims.

How does the patent compare with broader pilocarpine presbyopia patents?

US Patent 11,129,812 appears to occupy a formulation-specific position within the pilocarpine presbyopia field.

Patent strategy	Typical scope	Relationship to US 11,129,812
General pilocarpine treatment claim	Treating presbyopia with a miotic agent	Potentially broader but may not require the claimed excipients
Concentration claim	Pilocarpine within a defined percentage range	May overlap with the 0.4% limitation
Composition claim	Pilocarpine plus polymers, buffers or stabilizers	Potentially overlapping and commercially important
Method-of-use claim	Treating specified patient groups or visual conditions	May overlap with claim 5
Duration claim	Sustained effect for a specified period	May overlap with claims 3, 11 and 12
Delivery-system claim	Bottle, insert, gel, implant or controlled-release system	May be complementary rather than duplicative
Manufacturing claim	Preparation, sterilization or filling process	Can create independent manufacturing exposure

The principal competitive issue is not whether pilocarpine is generally known. Pilocarpine has long-standing ophthalmic use. The issue is whether the particular low-dose formulation, polymer combination, stabilizer system, and presbyopia use are separately protected by valid and enforceable claims.

When does US Patent 11,129,812 lose exclusivity?

The patent's exact expiration date depends on its earliest effective nonprovisional priority date, any patent-term adjustment, terminal disclaimer, patent-term extension and other USPTO term data. The grant date alone does not establish the expiration date.

For a standard US utility patent, the nominal term is generally 20 years from the earliest effective US nonprovisional filing date, subject to statutory adjustments under 35 U.S.C. §§ 154 and 156.[1] A regulatory patent-term extension may be available for qualifying products, but the extension is limited and does not automatically apply to every patent covering an approved drug.

A commercial exclusivity analysis should therefore distinguish:

Patent expiration;
FDA chemical exclusivity;
FDA orphan-drug exclusivity, if applicable;
Pediatric exclusivity;
Regulatory approval date;
Orange Book-listed patents; and
Any later-granted continuation patents.

FDA regulatory exclusivity

Pilocarpine hydrochloride is an established active ingredient. A later approval of a new concentration, formulation, delivery system or indication may qualify for a period of FDA market exclusivity under the applicable approval pathway, but the precise period depends on the submitted application and FDA designation.

FDA regulatory exclusivity is separate from the patent term. A generic or abbreviated application may be blocked by regulatory exclusivity even when a patent is vulnerable, while a patent may continue after regulatory exclusivity ends.[2]

What is the Orange Book status of US Patent 11,129,812?

Orange Book listing must be evaluated against the approved reference product and the patent declaration submitted by the NDA holder. A patent may be:

Listed as a drug-substance patent;
Listed as a drug-product or formulation patent;
Listed as a method-of-use patent;
Subject to a patent-use code;
Declared under Paragraph I, II, III or IV; or
Omitted from the Orange Book even though it remains relevant in private litigation or licensing.

The supplied claim language is principally a method-of-use claim with formulation limitations. Its Orange Book listing potential therefore depends on whether the patented method corresponds to an approved indication and whether the patent meets FDA listing standards. FDA's Orange Book database, patent-listing publications and the approved product label should control the current listing analysis.[2]

A patent that is not listed in the Orange Book can still create infringement risk under 35 U.S.C. § 271, but it generally will not create the same automatic Hatch-Waxman litigation pathway as a listed patent.

Which companies are challenging the patent through Paragraph IV?

A Paragraph IV challenge is product-specific and depends on an ANDA applicant identifying the relevant listed patent in its certification. The existence of US Patent 11,129,812 does not establish that a Paragraph IV notice has been served.

The relevant risk indicators are:

An approved or tentatively approved generic pilocarpine ophthalmic product;
An ANDA referencing a product covered by the patent;
A Paragraph IV certification;
A 45-day patent-infringement action by the NDA holder;
A 30-month stay, where applicable; and
A first applicant claiming 180-day generic exclusivity.

The patent's method-of-treatment structure can complicate ANDA litigation. A generic applicant may rely on a section viii statement and carve out a patented indication if the approved labeling can omit the protected use. That strategy is less effective where the formulation itself is required for the approved indication or where the label necessarily encourages the patented use.[3]

No particular challenger, settlement agreement or Paragraph IV litigation should be inferred solely from the claim language.

What patent litigation affects US Patent 11,129,812?

The central litigation questions are:

Whether the accused formulation contains all three specified active or functional ingredients at approximately the claimed concentrations.
Whether the product is used to correct presbyopia through pupil-size change.
Whether "about" is construed broadly enough to reach the accused concentration.
Whether the duration and night-vision limitations are definite and objectively measurable.
Whether claim 1 improperly combines formulation and method limitations in a way that creates enablement or written-description issues.
Whether prosecution amendments narrowed the claim scope.
Whether continuation patents preserve broader claims after this patent expires.

The highest-value evidence would usually include the accused product label, formulation dossier, clinical protocols, stability data, pupilometry results and patent prosecution history. Claim construction will likely determine whether the case turns on formulation identity or clinical mechanism.

How strong is the patent estate?

The patent is strongest against a product that copies the claimed formulation architecture and markets it for presbyopia. Its principal strengths are:

A defined combination of active ingredient and two viscosity or residence-time modifiers;
A concentration target commercially aligned with low-dose presbyopia therapy;
Functional claims directed to duration and night vision;
Patient-population coverage extending beyond uncomplicated age-related presbyopia; and
Multiple dosage-form and administration-route claims.

Its principal weaknesses are:

The independent claim is narrow and formulation-dependent;
The use of "about" may invite claim-construction disputes;
The mechanism limitation may require clinical proof;
Duration and visual-field limitations may raise measurement questions;
A competitor can potentially alter one polymer or concentration;
Method claims may be harder to enforce against an unlabeled or carved-out generic use; and
Patent strength cannot be assessed from the issued claims alone without prosecution history, specification support and family-claim review.

The patent should be treated as a meaningful blocking right for a matching 0.4% pilocarpine formulation, but not as a complete barrier to all pharmacologic presbyopia products.

What generic launch risks exist?

A generic launch could proceed through several scenarios:

Launch scenario	Risk profile
Same 0.4% pilocarpine, same polymers and presbyopia labeling	High infringement exposure
Same active concentration but different polymers	Lower literal risk under claim 1, subject to equivalents and other patents
Different pilocarpine concentration	Potentially lower risk, depending on concentration claims in related patents
Section viii carve-out of presbyopia indication	Regulatory and litigation risk depends on remaining label language
505(b)(2) product with modified formulation	Potentially significant patent and regulatory exposure
Non-pilocarpine presbyopia therapy	Primarily outside this patent, subject to separate patent families
Compounded product	Patent exposure may remain, but enforcement and regulatory issues differ

For a company developing a competing product, the most important freedom-to-operate issue is whether the final formulation reproduces the three-component concentration profile. A product that differs in only one excipient may require a doctrine-of-equivalents analysis rather than providing a clean clearance.

What manufacturing and geographic barriers apply?

The issued US patent is enforceable in the United States. Parallel foreign rights depend on national filings, granted claims, patent-term status and local prosecution outcomes. A US patent does not block manufacture entirely outside the United States unless additional jurisdictional rights or importation theories apply.

Manufacturing exposure can arise from:

Importing a product made by a process that practices a valid US process claim;
Selling or inducing use of a product with instructions for the patented presbyopia method;
Supplying a formulation component combination specifically adapted for the claimed use; and
Commercializing a product whose approved labeling directs the patented administration.

The supplied claims do not independently identify a manufacturing process. Manufacturing risk must therefore be assessed against related family patents, continuation applications and foreign counterparts rather than these claims alone.

Key Takeaways

US Patent 11,129,812 centers on a presbyopia treatment method using approximately 0.4% pilocarpine hydrochloride.
The claimed formulation also requires approximately 0.1% sodium hyaluronate and 0.8% hydroxypropyl methylcellulose.
Claim 1 is commercially meaningful but narrower than a general pilocarpine or presbyopia patent.
Claims 3, 11 and 12 target duration and functional performance, including effects lasting up to 8, 12 or 24 hours.
Claim 5 expands coverage to post-cataract, post-corneal-procedure, contact-lens, spectacle and higher-order-aberration patient groups.
The most direct generic risk involves a product reproducing the claimed formulation and carrying presbyopia-oriented labeling.
Changing one polymer, the pilocarpine salt, the concentration or the delivery system may reduce literal infringement risk.
Patent expiration cannot be calculated reliably from the grant number alone; the earliest effective filing date, patent-term adjustment, terminal disclaimers and any extension must be reviewed.
Orange Book status and Paragraph IV exposure are product-specific and cannot be established solely from the issued claims.
The patent is likely most valuable as part of a broader family covering formulation, method of use, delivery, manufacturing and follow-on commercial products.

FAQs About US Patent 11,129,812

Does US Patent 11,129,812 cover Vuity?

The claim language supplied does not cover every pilocarpine product. A product would face the strongest exposure if it contains approximately 0.4% pilocarpine hydrochloride, approximately 0.1% sodium hyaluronate and approximately 0.8% hydroxypropyl methylcellulose and is used to treat presbyopia through pupil-size change.

Does the patent cover preservative-free pilocarpine eye drops?

The supplied claims do not expressly require a preservative-free formulation. A preservative-free product may still fall within the claims if it contains the claimed ingredients and satisfies the method limitations.

Can a generic avoid the patent by changing the concentration from 0.4%?

A materially different concentration may avoid literal infringement of the concentration limitation, but the result depends on the construction of "about 0.4%" and any related patents with broader concentration ranges.

Does the patent cover treatment of presbyopia after cataract surgery?

Yes. Claim 5 expressly identifies subjects who underwent cataract surgery. The product must still satisfy the inherited limitations of claim 1.

Is a biosimilar challenge relevant to this patent?

No. Pilocarpine hydrochloride is a small-molecule active ingredient, so the principal competitive pathway is an ANDA or, for a modified formulation or indication, potentially a 505(b)(2) application. Biosimilar procedures generally do not apply.

References

United States Patent and Trademark Office. (2024). Patent term adjustment and patent term extension guidance. U.S. Department of Commerce. https://www.uspto.gov
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Refuse-to-receive standards. https://www.fda.gov

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Orasis Pharms	QLOSI	pilocarpine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	217836-001	Oct 17, 2023		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				TREATMENT OF PRESBYOPIA	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2017311636	⤷ Start Trial
Australia	2023226732	⤷ Start Trial
Brazil	112019002967	⤷ Start Trial
Canada	3031370	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 11,129,812

Which drugs does patent 11,129,812 protect, and when does it expire?

Summary for Patent: 11,129,812